Eur Rev Med Pharmacol Sci 2023; 27 (10): 4536-4543
DOI: 10.26355/eurrev_202305_32460

LncRNA FOXD2-AS1 facilitates the progression of hepatocellular carcinoma by regulating TWIST1

G. Chen, W.-L. Zhang, S.-M. Zhang, K.-L. Tang, Y. Zhang

Department of Hepatobiliary Surgery III, Guizhou Provincial People’s Hospital, Guiyang, China. drzhangwanli@hust.edu.cn


OBJECTIVE: The study aimed at elucidating the role of FOXD2-AS1 in facilitating the malignant progression of hepatocellular carcinoma (HCC) by regulating TWIST1.

PATIENTS AND METHODS: Relative levels of FOXD2-AS1 and TWIST1 in HCC tissues classified by tumor size and tumor node metastasis (TNM) staging were detected by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The Kaplan-Meier method was applied to assess the prognostic potential of FOXD2-AS1 in HCC patients, followed by survival rate comparison using a log-rank test. After the knockdown of FOXD2-AS1 in HepG2 cells, the viability and migratory abilities were examined by Cell Counting Kit-8 (CCK-8) and transwell assay, respectively. The subcellular distribution of FOXD2-AS1 was detected. Finally, the involvement of TWIST1 in the regulation of HCC cell functions influenced by FOXD2-AS1 was explored.

RESULTS: FOXD2-AS1 was upregulated in HCC tissues, especially large tumor size or stage III-IV cases. High levels of FOXD2-AS1 predicted poor prognosis in HCC patients. FOXD2-AS1 was mainly distributed in the nucleus, and knockdown of FOXD2-AS1 weakened proliferative and migratory abilities in HepG2 cells. TWIST1 was upregulated in HCC tissues, which was positively correlated to FOXD2-AS1 level. The overexpression of TWIST1 could reverse the inhibited proliferative and migratory abilities in HepG2 cells with FOXD2-AS1 knockdown.

CONCLUSIONS: FOXD2-AS1 facilitates the progression of HCC by upregulating TWIST1.

Free PDF Download

To cite this article

G. Chen, W.-L. Zhang, S.-M. Zhang, K.-L. Tang, Y. Zhang
LncRNA FOXD2-AS1 facilitates the progression of hepatocellular carcinoma by regulating TWIST1

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 10
Pages: 4536-4543
DOI: 10.26355/eurrev_202305_32460